WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral pill for high-risk patients.
  • The expert panel conditionally recommended molnupiravir for patients with non-severe disease at high risk of hospitalization, such as the immunocompromised, the unvaccinated, older people, and those with chronic conditions.
  • The recommendation was based on new data from six clinical trials involving 4,796 patients.
  • Related: See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization.
  • Since molnupiravir's U.S. authorization in December, demand for the pill among COVID-19 patients has taken a hit from comparatively low efficacy.
  • The panel also updated its guidance for the use of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) casirivimab-imdevimab COVID-19 antibody cocktail. 
  • It now recommends the drug only for people who are not infected with omicron as new data has shown it is not effective against the variant.
  • Price Action: MRK shares closed 0.70% higher at $77.21 on the last check Thursday.
  • Photo by Thomas Breher from Pixabay

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 Coronavirus